<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03727295</url>
  </required_header>
  <id_info>
    <org_study_id>SZDX-1</org_study_id>
    <nct_id>NCT03727295</nct_id>
  </id_info>
  <brief_title>Idebenone Treatment of Early Parkinson's Diseasesymptoms</brief_title>
  <acronym>ITEP</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      On May 30,2018 ,Investigators intend to conduct a multicenter, randomized, double-blind,&#xD;
      placebo-controlled study of idebenone in the treatment of early-stage Parkinson's disease&#xD;
      with motor and non-motor symptoms which is to observe the therapeutic effect of idebenone on&#xD;
      motor symptoms and non-motor symptoms in patients with early Parkinson's disease。&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trail was a multicenter, parallel, randomized, double-blind, placebo-controlled&#xD;
      study led by Professor Liu Chunfeng from the Second Affiliated Hospital of Suzhou University&#xD;
      which consisted of 15 sub-centers with a total of 180 subjects.&#xD;
&#xD;
      This clinical study is divided into two phases:&#xD;
&#xD;
      The first stage: double-blind period, 24 weeks. Three queues containing idebenone 180&#xD;
      mg/d,360 mg/d and placebo.&#xD;
&#xD;
      The second stage: open label extension period, 24 weeks. All enrolled participants continued&#xD;
      to take idebenone 180 mg/d to study the long-term effects of idebenone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the efficacy on motor symptoms and non-motor symptoms</measure>
    <time_frame>48weeks</time_frame>
    <description>UPDRS-III Hoehn-Yahr classification Olfactory function test Anxiety and depression: Anxiety and Depression Scale (HAD)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Oxidative Stress is an Important Cause of Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>The control group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 cases, idebenone 180mg/d, 3 times / day, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 cases, idebenone 360mg/d, 3 times / day, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60 cases, placebo, 3 times / day, oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone/placebo</intervention_name>
    <description>The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo</description>
    <arm_group_label>The control group 1</arm_group_label>
    <arm_group_label>The control group 2</arm_group_label>
    <arm_group_label>The placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Male or female, age &gt; 30 years old, ≤ 80 years old;&#xD;
&#xD;
          -  (2) Conforms to the &quot;Diagnostic Criteria for Parkinson's Disease&quot; developed by the&#xD;
             2015 International Association of Sports Disabilities (MDS);&#xD;
&#xD;
          -  (3) Patients with early Parkinson's disease, duration &lt;3 years, Hoehn-Yahr&#xD;
             classification:1-3, MMSE scale score ≥ 24 points;&#xD;
&#xD;
          -  (4)Receiving a stable dose of dopamine agonist or monoamine oxidase type B inhibitor&#xD;
             for treatment before the enrollment;&#xD;
&#xD;
          -  (5) The subjects need to sign the Informed Consent Form（ICF）&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1)Patients with disturbance of consciousness, aphasia and mental illness; patients&#xD;
             with major depression (HAD scale score ≥ 15 points)&#xD;
&#xD;
          -  (2)Patients with Parkinson's superimposition syndrome and patients with secondary&#xD;
             Parkinson's syndrome (hepatolenticular degeneration, hepatic encephalopathy,&#xD;
             cerebellar disease, hydrocephalus, parathyroid disease, etc.)&#xD;
&#xD;
          -  (3)Patients who have long-term use of dopamine blockers (such as potent neuroleptics,&#xD;
             sibutramine, reserpine, metoclopramide, etc.);&#xD;
&#xD;
          -  (4)Patients who have taken coenzyme Q10 or idebenone within three months;&#xD;
&#xD;
          -  (5) Patients taking amantadine and levodopa need to stop taking the drug for more than&#xD;
             one month before the enrollment;&#xD;
&#xD;
          -  (6)Patients with severe cardiopulmonary dysfunction, liver and kidney dysfunction&#xD;
             (more than 3 times normal);&#xD;
&#xD;
          -  (7)Patients who cannot cooperate with the neuropsychological test;&#xD;
&#xD;
          -  (8) Patients with poor compliance, not following the prescribed treatment regimen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chun Feng Liu, Professor</last_name>
    <phone>13606210609</phone>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2018</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idebenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

